Compare CVU & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVU | PRPO |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 38.3M |
| IPO Year | 1996 | 2000 |
| Metric | CVU | PRPO |
|---|---|---|
| Price | $4.95 | $19.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.5K | ★ 41.8K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $69,262,124.00 | $24,049,000.00 |
| Revenue This Year | N/A | $233.72 |
| Revenue Next Year | N/A | $22.61 |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $2.02 | $18.50 |
| 52 Week High | $5.98 | $33.63 |
| Indicator | CVU | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 24.89 |
| Support Level | $4.65 | N/A |
| Resistance Level | $5.33 | $24.54 |
| Average True Range (ATR) | 0.17 | 0.90 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 38.81 | 3.19 |
CPI Aerostructures Inc is engaged in the manufacturing of structural aircraft parts for fixed-wing aircraft and helicopters in both the commercial and defense markets in the United States. It also provides engineering, program management, supply chain management and kitting, and Maintenance Repair and Overhaul (MRO) services. CPI also acts as a subcontractor to prime aircraft manufacturers in the production of commercial aircraft parts. CPI Aero supplies the E-2D Advanced Hawkeye surveillance aircraft, the A-10 Thunderbolt attack jet, the Gulfstream G650, the UH-60 BLACK HAWK helicopter, and the S-92 helicopter, and others.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.